Carlumab

Carlumab

Carlumab (pronunciation: /kɑːrˈluːmæb/), also known as CNTO 888, is a monoclonal antibody designed for the treatment of cancer and inflammatory diseases. It was developed by Centocor, a subsidiary of Johnson & Johnson.

Etymology

The name "Carlumab" is derived from the International Nonproprietary Names (INN), where "car" refers to cardiovascular conditions, "lu" to the human source of the monoclonal antibody, and "mab" is indicative of its status as a monoclonal antibody.

Mechanism of Action

Carlumab works by targeting and inhibiting the chemokine CCL2, also known as monocyte chemoattractant protein 1 (MCP-1). This chemokine is involved in the recruitment of monocytes to sites of inflammation and tumors, thus Carlumab's inhibition of CCL2 can help reduce inflammation and tumor growth.

Clinical Trials

Carlumab has undergone Phase I and II clinical trials for various conditions, including metastatic prostate cancer, rheumatoid arthritis, and lung cancer. However, as of now, it has not been approved for use by any major regulatory authority.

Related Terms

• Monoclonal Antibody
• Chemokine
• Monocytes
• Inflammation
• Tumor
• Clinical Trials
• Prostate Cancer
• Rheumatoid Arthritis
• Lung Cancer

External links

• Medical encyclopedia article on Carlumab
• Wikipedia's article - Carlumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski